Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases. Tribune Therapeutics was founded by Dr. Kaasbøll, Professor Attramadal and Mr. Vo Beiske together with HealthCap and Novo Seeds in 2020. Tribune Therapeutics has in-licensed an asset from Inven2, one of the largest technology transfer offices in the Nordic region.
Management
Ole J. Kaasbøll, MD, PhD
CSO
Georg Vo Beiske, MPharm
CEOBoard of Directors
Jonas Hansson, MPharm, MBA
Chairman of the Board
Jacob Gunterberg, MSc
Board Member
Jørgen S. Petersen, MD, PhD, MBA
Board Member
Elias Papatheodorou
Board Member
João Ribas, PhD
Board MemberOle J. Kaasbøll, MD, PhD
CSO, Board MemberOur Science
Tribune Therapeutics is developing novel medicines to treat patients with fibrotic disease. The medicines target the CCN protein family. The CCN protein family is a group of signaling proteins central to the development of fibrosis; the process of exaggerated scar tissue formation. The most famous protein in the CCN family is CCN2, also known as Connective Tissue Growth Factor (CTGF). However, several of the other CCN family members have also been shown to be important drivers of fibrosis, and thus broader inhibition has a greater anti-fibrotic potential than solely targeting CCN2.
Careers
We are a science driven biotech company committed to improving patients’ lives. We are always looking to connect with people who have pharmaceutical development experience and share our goals. Leave us a message in the contact section below if you are curious about opportunities at Tribune.
Contact
Tribune Therapeutics AB
C/O Healthcap VIII Advisor Ab
Engelbrektsplan 1
114 34 Stockholm
Tribune Therapeutics AS
C/O Sharelab
Gaustadalleen 21
0349 Oslo
